Teva Upbeat On Partnered Biosimilars With EU Ranibizumab Set For 2022
‘We Are Addressing Some 80% Of The Value Going Off-Patent In The Coming Years’
Teva is confident that its partnered biosimilar programs – roughly half of its pipeline – will not dilute its margins, as it gears up to launch a biosimilar Lucentis product in the EU this year while pushing through other allied and internal assets in the US.
